Alfonso Rubio-Navarro

Dr. Alfonso Rubio-Navarro


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MHMelania Guerrero Hue
Melania Guerrero Hue
CGCristina García‐Caballero
Cristina García‐Caballero
APAlejandra Palomino‐Antolín
Alejandra Palomino‐Antolín
ARAlfonso Rubio-Navarro
Alfonso Rubio-Navarro
CVCristina Vázquez‐Carballo
Cristina Vázquez‐Carballo
Juan Antonio MorenoJuan Antonio Moreno
Juan Antonio Moreno
Acute kidney injury is a common complication of rhabdomyolysis. A better understanding of this syndrome may be useful to identify novel therapeutic targets because there is no specific treatment so far. Ferroptosis is an iron‐dependent form of regulated nonapoptotic cell death that is involved in renal injury. In this study, we investigated whether ferroptosis is associated with rhabdomyolysis‐mediated renal damage, and we studied the therapeutic effect of curcumin, a powerful antioxidant with renoprotective properties. Induction of rhabdomyolysis in mice increased serum creatinine levels, endothelial damage, inflammatory chemokines, and cytokine expression, alteration of redox balance (increased lipid peroxidation and decreased antioxidant defenses), and tubular cell death. Treatment with curcumin initiated before or after rhabdomyolysis induction ameliorated all these pathologic and molecular alterations. Although apoptosis or receptor‐interacting protein kinase (RIPK)3‐mediated necroptosis were activated in rhabdomyolysis, our results suggest a key role of ferroptosis. Thus, treatment with ferrostatin 1, a ferroptosis inhibitor, improved renal function in glycerol‐injected mice, whereas no beneficial effects were observed with the pan‐caspase inhibitor carbobenzoxy‐valyl‐alanyl‐aspartyl‐( O ‐methyl)‐fluoromethylketone or in RIPK3‐deficient mice. In cultured renal tubular cells, myoglobin (Mb) induced ferroptosis‐sensitive cell death that was also inhibited by curcumin. Mechanistic in vitro studies showed that curcumin reduced Mb‐mediated inflammation and oxidative stress by inhibiting the TLR4/NF‐κB axis and activating the cytoprotective enzyme heme oxygenase 1. Our findings are the first to demonstrate the involvement of ferroptosis in rhabdomyolysis‐associated renal damage and its sensitivity to curcumin treatment. Therefore, curcumin may be a potential therapeutic approach for patients with this syndrome.—Guerrero‐Hue, M., García‐Caballero, C., Palomino‐Antolín, A., Rubio‐Navarro, A., Vázquez‐Carballo, C., Herencia, C., Martín‐Sanchez, D., Farré‐Alins, V., Egea, J., Cannata, P., Praga, M., Ortiz, A., Egido, J., Sanz, A. B., Moreno, J. A. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis‐mediated cell death. FASEB J. 33,8961–8975 (2019). www.fasebj.org

1 October 2015 in Kidney and Blood Pressure Research
Verified
Journal Article
Open access
NPNayara Panizo
Nayara Panizo
ARAlfonso Rubio-Navarro
Alfonso Rubio-Navarro
JAJuan Manuel Amaro-Villalobos
Juan Manuel Amaro-Villalobos
JEJesús Egido
Jesús Egido
Juan Antonio MorenoJuan Antonio Moreno
Juan Antonio Moreno
Rhabdomyolysis is a syndrome caused by injury to skeletal muscle that usually leads to acute kidney injury (AKI). Rhabdomyolysis has been linked to different conditions, including severe trauma and intense physical exercise. Myoglobin-induced renal toxicity plays a key role in rhabdomyolysis-associated kidney damage by increasing oxidative stress, inflammation, endothelial dysfunction, vasoconstriction, and apoptosis. New drugs that target the harmful effects of myoglobin have been recently developed, and some have been proven to be successful in animal models of acute renal failure secondary to rhabdomyolysis. This review aims to provide a comprehensive and updated overview of the pathological mechanisms of renal damage and describes new therapeutic approaches to this condition based on novel compounds that target key pathways involved in myoglobin-mediated kidney damage.

7 November 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NGNicolás Gómez-Banoy
Nicolás Gómez-Banoy
JGJ. Sawalla Guseh
J. Sawalla Guseh
GLGe Li
Ge Li
ARAlfonso Rubio-Navarro
Alfonso Rubio-Navarro
TCTong Chen
Tong Chen
JLJames C. Lo
James C. Lo

31 December 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
MHMelania Guerrero Hue
Melania Guerrero Hue
SRSandra Rayego-Mateos
Sandra Rayego-Mateos
CVCristina Vázquez
Cristina Vázquez
APAlejandra Palomino
Alejandra Palomino
CGCristina García-Caballero
Cristina García-Caballero
Juan Antonio MorenoJuan Antonio Moreno
Juan Antonio Moreno
Chronic kidney disease (CKD) is one of the fastest-growing causes of death and is predicted to become by 2040 the fifth global cause of death. CKD is characterized by increased oxidative stress and chronic inflammation. However, therapies to slow or prevent CKD progression remain an unmet need. Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that plays a key role in protection against oxidative stress and regulation of the inflammatory response. Consequently, the use of compounds targeting Nrf2 has generated growing interest for nephrologists. Pre-clinical and clinical studies have demonstrated that Nrf2-inducing strategies prevent CKD progression and protect from acute kidney injury (AKI). In this article, we review current knowledge on the protective mechanisms mediated by Nrf2 against kidney injury, novel therapeutic strategies to induce Nrf2 activation, and the status of ongoing clinical trials targeting Nrf2 in renal diseases.

5 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BMBeatriz Martín-Fernández
Beatriz Martín-Fernández
ARAlfonso Rubio-Navarro
Alfonso Rubio-Navarro
ICIsabel Cortegano
Isabel Cortegano
SBSandra Ballesteros
Sandra Ballesteros
MAMario Alía
Mario Alía
Juan Antonio MorenoJuan Antonio Moreno
Juan Antonio Moreno
We aimed to evaluate macrophages heterogeneity and structural, functional and inflammatory alterations in rat kidney by aldosterone + salt administration. The effects of treatment with spironolactone on above parameters were also analyzed. Male Wistar rats received aldosterone (1 mgkg-1d-1) + 1% NaCl for 3 weeks. Half of the animals were treated with spironolactone (200 mg kg-1d-1). Systolic and diastolic blood pressures were elevated (p<0.05) in aldosterone + salt–treated rats. Relative kidney weight, collagen content, fibronectin, macrophage infiltrate, CTGF, Col I, MMP2, TNF-α, CD68, Arg2, and SGK-1 were increased (p<0.05) in aldosterone + salt–treated rats, being reduced by spironolactone (p<0.05). Increased iNOS and IFN-γ mRNA gene expression (M1 macrophage markers) was observed in aldosterone + salt rats, whereas no significant differences were observed in IL-10 and gene ArgI mRNA expression or ED2 protein content (M2 macrophage markers). All the observed changes were blocked with spironolactone treatment. Macrophage depletion with liposomal clodronate reduced macrophage influx and inflammatory M1 markers (INF-γ or iNOS), whereas interstitial fibrosis was only partially reduced after this intervention, in aldosterone plus salt-treated rats. In conclusion, aldosterone + salt administration mediates inflammatory M1 macrophage phenotype and increased fibrosis throughout mineralocorticoid receptors activation.

1 January 2012 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
Juan Antonio MorenoJuan Antonio Moreno
Juan Antonio Moreno
CMCatalina Martín-Cleary
Catalina Martín-Cleary
EGEduardo Gutiérrez
Eduardo Gutiérrez
ARAlfonso Rubio-Navarro
Alfonso Rubio-Navarro
AOAlberto Ortiz
Alberto Ortiz
JEJesús Egido
Jesús Egido
Haematuria is a frequent manifestation of glomerular disease. However, nephrologists devote more attention to the monitoring and therapeutic targeting of another key manifestation of glomerular injury, proteinuria. Recent reports have propelled haematuria to the forefront of clinical nephrology. Thus, glomerular macroscopic haematuria is associated with the development of acute kidney injury (AKI) with predominant tubular cell damage and there is increasing evidence for the negative impact of glomerular haematuria-associated AKI on long-term renal function outcome both in the context of IgA nephropathy and in anticoagulated patients. In addition, an epidemiological association between isolated microscopic haematuria in young adults and long-term incidence of end-stage renal disease has been described. Finally, a clearer understanding of how haematuria may cause tubular injury is emerging through detailed histological assessment of human biopsies and experimental models of haemoglobin-mediated nephrotoxicity.